TCRT

Alaunos Therapeutics, Inc.

$1.71

2.40%

SectorHealthcareIndustryBiotechnologyCountryUnited States

Overview AI Brief ChartChart & Performance Financials ExposureRevenue Exposure FilingsFilings & Red Flags ScoresScores & Valuation News Analysts InsidersInsiders & Short Interest Ownership

Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.

Source: Yahoo Finance

Market Cap$5.9M

Dividend Yield0.00%

Beta0.54

AI summary

Price & performance

1M+160.8%

3M+52.7%

YTD-4.6%

1Y+2.0%

52-week range—

Beta0.54

Full chart and returns against a benchmark

Q-Score

23/ 100

Quality against peers; 50 is the peer median.

Growth30

Risk28

Performance53

Valuation24

Profitability4

Leverage26

Sentiment—

Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$5K-50.0%

Net income-$4.2M

Net margin—

Historical fundamentals

Red flags in filings

3active red flags

Going-concern doubtMar 31, 2026

Material weakness in controlsMar 31, 2026

Exchange listing noticeOct 21, 2026

Filings, findings and the timeline

Revenue exposure

0%of revenue from outside the US

United States100%

Regions, segments, customers and suppliers

Valuation

TCRTIndustryP/E—89.69P/S—11.88EV/EBITDA—67.10P/B9.026.22PEG—4.02

Dividend yield0.00%

Every valuation metric

Historical Fundamentals

Revenue

Net Income

Showing the last 4 periods. Pro adds the full annual and quarterly history and 20+ more metrics to chart.

Latest Results

The latest fiscal year and quarter, each against the same period a year earlier, from SEC filings.

Metric	FY 2025	vs a year before	Q2 2026	vs a year before
Revenue	$5K	-50.0%	—	—
Net Income	-$4.2M	—	-$952K	—

Q-Scores

OverallCombines the categories below, except Sentiment

Industry 5723

Growth

Industry 7930

Risk

Industry 5528

Performance

Industry 6653

Valuation

Industry 2524

Profitability

Industry 474

Leverage

Industry 6826

Key Metrics

Fundamentals: trailing twelve months to Jun 2026, from the latest 10-K and 10-Qs.

Market Beta (5-factor)

IM 0.72SM 0.780.54

Market Cap

5.9M

Dividend Yield

IM 0.00%SM 0.00%0.00%

Volume

IM 693.1KSM 741.7K7.5M

Industry Market Share

0.00%

Sector Market Share

0.00%

IM industry median · SM sector median: the typical company the value is compared with. The /100 is its score against those peers.

Comparable Companies

The companies closest in size in Biotechnology (filled from its sector when there are few), with the median and rank across all 571 in the industry.

Company	Market cap	P/S	P/B	FCF yield	Revenue growth	Op. margin	ROE	Debt/equity
TCRTAlaunos Therapeutics, Inc.	$5.9M	—	9.0	-48.0%	-50.0%	—	-615.0%	0.0
JAGXJaguar Health, Inc.	$5.8M	0.2	1.2	-114.7%	135.5%	-93.1%	-747.5%	0.0
ACXPAcurx Pharmaceuticals, Inc.	$5.7M	—	0.7	-108.7%	—	—	-92.1%	0.0
KPRXKiora Pharmaceuticals, Inc.	$6.1M	—	0.4	-141.1%	—	—	-65.2%	0.0
CNSPCNS Pharmaceuticals, Inc.	$5.6M	—	0.3	-238.9%	—	—	-91.8%	0.0
AIMAIM ImmunoTech Inc.	$5.5M	58.0	0.7	-261.1%	-21.5%	—	-184.3%	0.9
CDIOCardio Diagnostics Holdings, Inc.	$5.5M	—	1.0	-105.1%	-3.8%	—	-113.4%	0.0
APREAprea Therapeutics, Inc.	$6.3M	—	0.2	-201.2%	—	—	-41.5%	0.0
SNTISenti Biosciences Holdings, Inc.	$5.4M	98.3	—	-703.8%	—	—	—	—
Industry median		7.7	2.2	-22.3%	12.8%	-76.9%	-60.8%	0.0
TCRT percentile		—	87th	34th	15th	—	2nd	39th